The T3D Therapeutics team, including John Didsbury, who was Chief Scientific Officer of DARA from 2005 to 2009, is comprised of leading experts in the field of PPAR science and are extremely familiar with the compound.
We believe they will apply the necessary resources to explore DB959 in multiple, potential high-value indications.
Importantly, the agreement affords DARA upfront considerations as well as future potential revenue based on progression of the DB959 developmental program."
previously reported that it was actively seeking to out-license DB959 as part of its strategic plan to focus on the commercialization of oncology supportive care products.
John Didsbury, Ph.D., Founder and Chief Executive Officer of T3D Therapeutics, commented, "The T3D Therapeutics team has a long history with DB959, and we plan to develop it as a transformational new therapy for the treatment of Alzheimer's disease.
Unlike other therapies in development that target a single pathology, typically the reduction or prevention of beta amyloid plaque buildup, T3D
expects DB959 will afford a multidimensional opportunity, with the potential to improve several Alzheimer's disease pathologies including addressing beta amyloid plaque issues.
Positive improvements in disease pathologies such as neuro-inflammation, neuronal cell loss, neurotransmitter deficits, tau neurofibrillary tangles, and insulin resistance / lowered cerebral glucose metabolism also are anticipated."
continued, "With today's highly competitive diabetes and dyslipidemia market, we believe that DB959 will be better positioned to address unmet medical needs for new central nervous system (CNS) therapies.